Health Care/Hospital
Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials
WUHAN, China and SAN DIEGO, Aug. 11, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth"), aChina's leading gene therapy company for ophthalmic diseases, announced the closing of nearly95 million USD in Series C+ financing. The round was co-led by Yangtze River-CMB International Indust...
2023-08-11 21:00
2358
Nano Labs to Announce First Half of 2023 Financial Results on August 15, 2023
HANGZHOU, China, Aug. 11, 2023 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider inChina, today announced that it will report its unaudited financial results for the first half of 2023...
2023-08-11 20:00
4637
Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer
SHANGHAI, Aug. 11, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical tr...
2023-08-11 17:00
3803
Move Aside Anti-Ageing, It's Age Reversal We're Talking Now
SINGAPORE, Aug. 11, 2023 /PRNewswire/ -- In the realm of medical progress, the horizon extends far beyond the battle against diseases. Now, the concept of "age reversal" — not merely slowing down or halting ageing — stands as a tangible reality. However, the validity and accuracy of ageing measur...
2023-08-11 13:49
1875
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...
2023-08-11 11:14
1791
WuXi XDC and Boostimmune Sign MOU for Integrated Services
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating ...
2023-08-11 08:30
1386
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating the tumor immune micr...
2023-08-11 08:30
4168
JUNG KWAN JANG Red Ginseng Samgyetang, a popular energizing food for hot summer days
A blend of chicken and red ginseng, an energizing recipe to revitalize during the hot summer months SEOUL, South Korea, Aug. 11, 2023 /PRNewswire/ -- How can we stay strong during the hot summer? Eating nourishing foods can be an uplifting strategy, particularly when lethargy tends to set in. Ac...
2023-08-11 08:00
3393
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China
- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and improving access of the drug to patients in the mainland ofChina - Antengene to receive up to RMB200 million in upfront payments,...
2023-08-11 08:00
2635
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...
2023-08-11 07:18
1818
YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023
GAITHERSBURG, Md., Aug. 10, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-08-11 04:30
4671
HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics
CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research service agreement with Nested Therapeutics, Inc. ("Nested"), a biotechnology company pioneering a next-generation precisi...
2023-08-10 21:30
1732
Datasea Launches Innovative "Intelligent Acoustics" Subsidiary in Delaware, Unveiling AI-Integrated Offerings for US Market
BEIJING, Aug. 10, 2023 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), a digital technology corporation engaged in three converging and innovative business segments inChina: intelligent acoustics, 5G messaging, and smart city technology, announced the inception of a who...
2023-08-10 21:30
3394
Standigm and Nashville Biosciences join to revolutionize early drug discovery
Companies will identify novel therapeutic targets using Standigm's explainable
AI and Nashville Biosciences' datasets
SEOUL, South Korea, Aug. 10, 2023 /PRNewswire/ -- Standigm
2023-08-10 21:07
1312
Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- August 10, 2023, in a groundbreaking development, Oricell Therapeutics Co., Ltd. ("Oricell") has received the green light for its Investigational New Drug (IND) application of OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed...
2023-08-10 21:00
2133
Clarity's theranostic prostate cancer trial advances to highest dose level
Highlights * Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 3 participants who received therapy with67Cu SAR-bisPSMA at the dose level of 8GBq. * No dose limiting toxicities (DLTs) ha...
2023-08-10 20:58
2234
Waterdrop Presents Advanced Digital Risk Management Solution at 2023 Inslab Insurance Technology Festival
BEIJING, Aug. 10, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, recently unveiled an innovative, digital intelligence-driven risk management approach at the20...
2023-08-10 19:41
4516
LyondellBasell Awarded the 2023 Global Medical Plastics Company of the Year by Frost & Sullivan
LyondellBasell is among the top three global polyolefin manufacturers in terms of capacity and sustainable solutions, catering to multiple industries, including pharmaceuticals and medical devices. SAN ANTONIO, Aug. 10, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the medical plasti...
2023-08-10 19:00
1701
Baird Medical Submits Disposable Microwave Ablation Needle and MWA System Application to U.S. FDA for Treatment of Soft Tissue Microwave Ablation
GUANGZHOU, China, Aug. 10, 2023 /PRNewswire/ -- Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina, today announced the 510(k) premarket notification submission of the Company's Disposabl...
2023-08-10 19:00
1744
AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reduction in patient-reported Subjective Units of Distress Scale (SUDS) score compared to placebo in a public speaking challenge (primary endpoint, p...
2023-08-10 15:49
4142
Week's Top Stories
Most Reposted
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
[Picked up by 350 media titles]
2024-06-19 11:00
Tan Xuguang: Enter South Korea, Full Focus on Business in the "Doorstep" Market
[Picked up by 335 media titles]
2024-06-16 19:38
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
[Picked up by 331 media titles]
2024-06-20 16:24
MoneyGram Announces Partnership with Rashid Khan to Promote the Company's Trusted and Reliable Services in Afghanistan and Around the World
[Picked up by 327 media titles]
2024-06-18 09:00
Tan Xuguang: Southeast Asia Product Exports Must Navigate with a "Battle Plan" and Transform
[Picked up by 322 media titles]
2024-06-18 15:45
Most Read
Tan Xuguang: Enter South Korea, Full Focus on Business in the "Doorstep" Market
2024-06-16 19:38
11742
Tan Xuguang: Southeast Asia Product Exports Must Navigate with a "Battle Plan" and Transform
2024-06-18 15:45
11474
MoneyGram Announces Partnership with Rashid Khan to Promote the Company's Trusted and Reliable Services in Afghanistan and Around the World
2024-06-18 09:00
10628
